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diagnoses during 2007 in the South-West region of Sweden. Sixty-two percent of the 
patients had at least one visit to the primary care, 35% had been treated as out-patient, 
9% had been treated by private physician, and 7% had been treated by in-patient 
care; 73% had at least one dispensed drug. The total health care cost, including drug 
cost, was 683 million SEK. 35% were from drugs and 23%, 26%, 14%, and 1% were 
from in-patient, out-patient, primary, and private care. During 2007 the average drug 
cost per patient, who utilize the current treatment, was 8847 SEK for drugs. The 
average cost for in-patient care was 64,576 SEK and 13,859 SEK for out-patient care. 
For primary and private care the average cost was 4268 SEK and 1342 SEK. CON-
CLUSIONS: The cost for antidepressant drugs was the largest part of the total health 
care cost for MDD, 35%. The in-patient care was the greatest cost per patient. The 
relevant question is what mix of drugs should be prescribed in order to minimize the 
total health care cost. Further research needs to be preformed.
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OBJECTIVES: Population based study to determine clinical consequences and eco-
nomic impact of using escitalopram (ESC) vs. citalopram (CIT) and venlafaxine (VEN) 
in patients initiating treatment for a new episode of major depression (MD), in real-life 
conditions of outpatient practice. METHODS: Observational, multicenter, retrospec-
tive study conducted using computerized medical records (administrative databases) 
of patients treated in six primary care centers and two hospitals between January 2003 
and March 2007. Study population: patients >20 years of age diagnosed with a new 
episode of MD who initiate treatment with ESC, CIT or VEN, and whithout any 
antidepressant treatment within the previous 6 months, who were followed for 18 
months or more. Main variables: socio-demographic variables, remission, comorbid-
ity, annual health care costs (medical visits, diagnostic and therapeutic tests, hospital-
izations, emergency room and psychoactive drugs prescribed) and non-health care 
costs (productivity loss at work). Statistical analyses: logistic regression and ANCOVA 
models. RESULTS: A total of 965 patients (ESC = 131; CIT = 491; VEN = 343) were 
included. ESC-treated patients were younger, with a higher proportion of males, and 
a lower speciﬁ c comorbidity (P < 0.01). ESC-treated patients achieved higher remission 
rates (58.0%) compared to CIT (38.3%) or VEN (32.4%) patients (P < 0.001) and 
had lower productivity work ESC (37.9 days) vs.CIT (32.7 days) or vs. VEN (43.8 
days), p = 0.042. No differences in average/unit costs of psychoactive drugs were 
observed between the ESC and CIT groups (c294.7 vs. c265.2), with higher costs seen 
in the VEN group (c643.0), p = 0.003. In the corrected model, total (health care and 
non-health care) costs were lower with ESC (c2276.2) vs. CIT (c3093.8), p = 0.047 
and VEN (c3801.2), p = 0.045. CONCLUSIONS: ESC appears to be dominant in the 
treatment of new MD episodes when compared to CIT and VEN, resulting in higher 
remission rates and lower total costs.
PMH26
COST ANALYSIS OF METHADONE MAINTENANCE THERAPY (MMT) 
PROGRAM IN MALAYSIA
Abdul Ghani N, Shaﬁ e AA, Hassali MAA
Universiti Sains Malaysia, Penang, Malaysia
OBJECTIVES: To analyze the cost of MMT treatment for patient with substance use 
disorder. METHODS: This was a retrospective study involving 185 opiate dependence 
patients who were receiving MMT treatment program in Malaysian’s government 
hospitals starting December 2005 until February 2010. The study was done from the 
provider perspective using activity based costing that includes both capital and vari-
able cost associated with MMT program. RESULTS: Most of the respondents were 
male (99%) with mean age of 38.5 years. Most (72.5%) of them were Malay and 
50.5% working in semi or unskilled manual job with basic salary less than MYR1000 
(US$312). Most (99.5%) were smoker with history of heroin addiction of more than 
10 years. The median length of MMT treatment was 14 months. Fifty-seven percent 
of the patients were suffering from chronic disease. The capital cost for MMT program 
was US$8013.16 and the variable cost of providing a month of treatment per patient 
was US$50.43. Approximately 47.19% of this was for methadone and personnel cost 
accounted for 31.94%. The variable cost was statistically higher (P < 0.05) in patients 
present of chronic disease. CONCLUSIONS: This study estimated the variable cost 
of MMT treatment per patient in Malaysia (US$50.43/month) is less expensive 
compare USA (US$220/month, Jones et al., 2009). These cost data may be useful to 
policymakers and researchers for further developing the program.
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OBJECTIVES: To describe new data on recent trends in U.S. psychiatric prescription 
drug spending and utilization over the period 2003 to 2008 and to understand drivers 
of those new trends. METHODS: SAMSA Spending Estimates were coupled with 
MEPS data to examine trends in mental health drug spending and utilization through 
2005. 1997–2008 Thomson Reuters MarketScan Commercial Claims data were used 
to decompose spending where: Total Expenditures = Price X Quantity, and ΔCost/
Enrollee = ΔCost/Day X ΔDays/User X ΔUsers/Enrollees. The following drugs were 
included in the analysis: Antidepressants, Antipsychotics, Stimulants, and Anxiolytic/
Sedative/Hypnotics. RESULTS: The average annual growth rate in mental health 
prescription drug spending dropped from 28% in 1998 to 3% in 2008. The rate of 
growth has stayed below 10% since 2005, and was negative in 2007. For persons 
with private insurance, the average annual expenditure growth rate overall was 6% 
during the years 2001–2008, where 2% was attributable to days/user, 2% was due 
to users per population, and 2% was due to cost/day. In contrast for the years 
1997–2001, the average growth rate overall was 18%, where 3% was attributable to 
days/user, 7% was due to users per population, and 8% was due to cost/day. 
CONCLUSIONS: Mental health prescription drug spending growth has slowed in 
recent years. This is due primarily to slower growth in additional users and slower 
price growth. The lower price growth is mainly due to generic entries starting in 2005, 
particularly within the antidepressant drug class.
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OBJECTIVES: To analyze the clinical and economic effects of the use of Pregabalin 
(PGB) in patients with refractory severe Generalized Anxiety Disorder (GAD) and 
severe concomitant depressive symptoms in daily medical practice. METHODS: Data 
were obtained from a post-hoc analysis of a 6-month, prospective, non-interventional 
study conducted in outpatient psychiatric clinics to ascertain the impact of broadening 
GAD diagnostic criteria. This before-after study included PGB naïve patients above 
18 years, with GAD (using DSM-IV criteria), refractory to anxiolytics for a minimum 
of 3 months, severe symptoms of anxiety (HAM-A > 24) and depression (MADRS > 
35), who received ﬂ exible doses of PGB either as monotherapy or add-on, per psy-
chiatrist judgment. Changes in HAM-A and MADRS and responders rates (reduction 
> 50% of baseline scoring) were the study end-points, together with health care 
resources utilization and corresponding costs. RESULTS: A total of 159 patients 
[69.2% women, mean age 45.9 (12.6) years] fulﬁ lled criteria for analysis. Ninety 
percent or more patients were previously exposed to benzodiazepines and/or antide-
pressants [mean 2.7 (1.3) drugs]. Adding PGB [mean dose: 223.1 (126.3) mg/day] 
reduced both anxiety and depressive symptoms, respectively, in HAM-A and MADRS 
scales, by −57.9% (from 35.5 + 5.8 to 14.8 + 9.4; P < 0.001, effect size: 3.57) and 
−58.1% (from 39.4 + 4.3 to 16.5 + 10.3; P < 0.001, effect size: 5.33). As a result, 
responder rates were 63.1% and 62.9%, respectively. Costs reductions in medical 
visits [−c1022 (−1,376; −669), P < 0.001] and hospitalizations [−c144 (−245;−44), p 
= 0.005], offset the higher incremental drug cost of PGB treatment [c353 (292; 415), 
P < 0.001] showing statistically reduction of health care costs; −c619 (−1,040;−197), 
p = 0.004. CONCLUSIONS: The use of Pregabalin resulted in both clinical and 
economic beneﬁ ts in patients with severe refractory GAD and concomitant severe 
depressive disorder. Patients experienced a signiﬁ cant improvement in their anxiety 
and depression symptoms, improvements which were associated with signiﬁ cant 
decreases in health care costs.
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OBJECTIVES: Patients with schizophrenia experience elevated rates of morbidity and 
mortality, largely due to an increased incidence of cardiovascular disease and diabetes. 
The STAR study showed that the metabolic side effects of aripiprazole treatment are 
less than that experienced by those receiving standard-of-care (SOC) antipsychotic 
treatment (olanzapine, queatipine or risperidone). This study estimates the difference 
in direct and indirect cost-consequences of diabetes and coronary heart disease (CHD) 
in schizophrenia patients treated with aripiprazole or SOC. METHODS: On the basis 
of the results provided by the STAR study, risks for diabetes and CHD were projected 
over a time horizon of 10 years in the Spanish setting using the Stern and Framingham 
models. The comparators were aripiprazole versus SOC. The prevalence and costs 
(direct and indirect) of diabetes and CHD were obtained from Spanish sources. All 
costs were inﬂ ated to 2009 costs using the Spanish Health System pay and prices 
index. RESULTS: The number of avoided diabetes cases (23.4 cases per 1,000 treated 
patients) in patients treated with aripiprazole compared to SOC was associated with 
estimated total (direct and indirect) cost saving of c27,798,018 over 10 years for the 
Spanish population. Similarly, with aripiprazole the number of avoided CHD events 
(3.7 events per 1,000 treated patients) yields an estimated total cost saving of 
c4,173,818 over 10 years. CONCLUSIONS: Compared with SOC, aripiprazole 
